Dr. Egolum is a heart failure cardiologist who practices at Georgia Heart Institute locations in Gainesville and Braselton. He serves as program director for the left ventricular assist device (LVAD) clinical program and program director for Northeast Georgia Medical Center’s Cardiovascular Disease Fellowship program. He joined Georgia Heart Institute in 2017 and has held several other leadership roles, including Chief of Cardiology for Northeast Georgia Health System and Medical Director of Georgia Heart Institute’s Heart Failure Treatment & Recovery Center.
Dr. Egolum received his medical degree from Howard University College of Medicine in Washington, DC. He graduated top 10% of his class and was inducted into the Alpha Omega Alpha Honors Society. He completed his residency in Internal Medicine and two fellowships from Vanderbilt University Medical Center in Nashville, Tennessee, one in General Cardiology and the second, in Advanced Heart Failure, and Transplant Cardiology. He served as Chief Fellow during his training at Vanderbilt. Dr. Egolum is board-certified in Advanced Heart Failure and Transplant Cardiology, Internal Medicine and Cardiovascular Disease.
Dr. Egolum has been honored with numerous awards for his scholarship, clinical practice, teaching and research. Since 2008, he has contributed to or has been lead author for more than 50 original research articles, book chapters and abstracts in peer reviewed publications and presented at national and international society meetings. Dr. Egolum is a member of the Heart Failure Society of America, the American College of Cardiology, the American College of Physicians, and the American Board of Internal Medicine. He has served on a national guideline writing committee and functions as an advisory consultant to several pharmaceutical/device companies. He is the principal investigator on several key Heart Failure clinical trials often being the top enroller nationwide. Additionally, Dr. Egolum has expertise and a specific interest in the care and management of patients with cardiac amyloidosis, pulmonary arterial hypertension and cardiac sarcoidosis.